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Abstract
The human intestinal microbiota performs many essential functions for the host. Antimicrobial agents, such as antibiotics
(AB), are also known to disturb microbial community equilibrium, thereby having an impact on human physiology. While an
increasing number of studies investigate the effects of AB usage on changes in human gut microbiota biodiversity, its
functional effects are still poorly understood. We performed a follow-up study to explore the effect of ABs with different
modes of action on human gut microbiota composition and function. Four individuals were treated with different
antibiotics and samples were taken before, during and after the AB course for all of them. Changes in the total and in the
active (growing) microbiota as well as the functional changes were addressed by 16S rRNA gene and metagenomic 454-
based pyrosequencing approaches. We have found that the class of antibiotic, particularly its antimicrobial effect and
mode of action, played an important role in modulating the gut microbiota composition and function. Furthermore, analysis
of the resistome suggested that oscillatory dynamics are not only due to antibiotic-target resistance, but also to fluctuations
in the surviving bacterial community. Our results indicated that the effect of AB on the human gut microbiota relates to the
interaction of several factors, principally the properties of the antimicrobial agent, and the structure, functions and
resistance genes of the microbial community.
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Introduction
Throughout evolution mammals have established symbioses
with microbial communities, which are located in different organs
and tissues of the body such as skin, mucosa, or the gastrointestinal
tract. The gut microbiota in humans is a particularly complex
ecosystem with few dominant phyla (Firmicutes, Bacteroidetes,
Proteobacteria and Actinobacteria) but show greater microbial
diversity at lower taxonomic levels and a high functional
redundancy [1,2]. The gut microbiota seems to be host-specific
and rather stable under non- or small perturbations [3] and is
involved in a large number of host beneficial functions such as
food processing, growth regulation of the intestinal epithelium,
development of the immune system, or protection against
pathogens [2,4,5]. Because of the essential role of the microbiota
in host life, imbalances in the gut microbial community may have
an important impact on human health. This is apparent in some
intestinal pathologies such as inflammatory bowel diseases or
antibiotic-associated diarrhea [6].
Systematic antibiotic (AB) therapy represents a major public
health problem because gut microbiota may be transformed into a
reservoir of antibiotic resistance genes, promoting the appearance
of harmful resistant strains [7,8,9,10]. It also suppresses some
protective members of the resident microbiota promoting over-
growth of opportunistic pathogens such as Clostridium difficile [11].
Moreover, AB therapy disturbs the gut microbiota and, concom-
itantly, affects human physiology, for instance carbohydrate
metabolism or immunity [7,12].
Antibiotic features such as class, spectrum or pharmacological
properties affect the gut microbiota in different ways [13]. In
addition, host-associated factors such as diet, life history, genetic or
health status, properties of the gut microbial ecosystem itself like
resistance and resilience, or even the interplay between the
microbiota and its host also have an effect on microbiota
composition and function. All these factors can mask changes
caused exclusively by antibiotics, representing a real challenge
when it comes to understand microbiota responses. Most recent
studies into the impact of antibiotics on the microbiota have
focused on the emergence of resistant strains, but few have
described their influence on the microbial community itself
[14,15,16,17,18]. These latter surveys, using 16S rRNA gene
sequencing, have shown that short and long-term AB courses
affect diversity and biomass of the intestinal microbiota, with
microbial composition resilience remaining deficient for long time
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after AB-treatment [15,16,17,18]. By contrast, the functional
impact of AB on the microbial ecosystem has been addressed less
frequently [19].
The use of the meta-‘‘omics’’ approaches (metagenomics,
metatranscriptomics, metaproteomics) has provided deeper in-
sights into microbial communities in different ecosystems
[2,20,21,22,23]. A recent integrated analysis has provided a better
understanding of the nature of the complex processes underlying
the whole human gut microbiota and its responses during beta-
lactamic-therapy [12].
In the present work we studied the effect of different antibiotics
on the human gut microbiota by a follow-up study comparing
microbial communities before, during and after AB therapy in four
individuals. We analyzed the changes in composition of the total
(16S rRNA gene) and active (16S rRNA transcripts) microbiota
throughout treatment. Furthermore, the functional analysis of the
total gene content of the community showed, for the first time,
how the mode of action and the antimicrobial effect of AB affected
the functional potential of the community. Finally, we described
the dynamics of resistance genes (i.e. the resistome) throughout the
study, paying particular attention to those that become resident
after AB-therapy.
Materials and Methods
Ethics statement
The study was approved by the Ethics Committee of the
Medical Faculty of the Christian-Albrechts University Kiel,
Germany. Informed written consent was obtained from all patients
involved in the study.
Sample collection and AB treatment regimen
Fecal samples were collected from four patients (herein referred
to as patient A, B, C and D) at the Department of Internal
Medicine of the University Hospital Schleswig-Holstein, Campus
Kiel, Germany (UK-SH). Patient A was treated with moxifloxacin
(400 mg/day) for 13 days. Moxifloxacin is a fourth-generation
synthetic fluoroquinolone antibacterial agent with a bactericidal
effect inhibiting cell replication. AB treatment for patient B
consisted of a combined therapy with penicillin G and clindamycin
on the day of admission, and subsequently with clindamycin alone
(36300 mg/day) for seven days. This semi-synthetic derivative
belongs to the lincosamide class exerting a bacteriostatic effect due
to the inhibition of protein synthesis. For patient C, AB therapy
was initiated with cefazolin (362 g/day) for seven days and
continued with ampicillin/sulbactam (26750 mg) for seven more
days. Patient D received an amoxicillin (361000 mg/day)
treatment. The antibiotics used for these two latter two patients
belong to the beta-lactam class and have a bactericidal effect
inhibiting cell envelope synthesis. Main features of patients and
therapy are shown in Table 1.
Fecal samples from patients (named A, B, C and D) were
collected on the day of admission, before the antibiotic treatment
(day 0), during and after AB therapy. In two cases (A and B), the
last sample was taken 3 days after therapy, in the other two cases
(B and D) the last sample was provided 7 and 28 days after
treatment, respectively (Table1). Patients did not present any
intestinal disorder. Samples were collected in sterile tubes and
stored at 280uC until further processing.
DNA extraction
Tubes containing fecal samples with sterile PBS (containing, per
liter, 8 g of NaCl, 0.2 g of KCl, 1.44 g of Na2HPO4, and 0.24 g
of KH2PO4 [pH 7.2]) were centrifuged at 1250 g and 4uC for 2
min to remove fecal waste. DNA was extracted from bacterial
pellets using QIAampH DNA Stool Kit (Quiagen) following the
manufacturer’s instructions. The product was concentrated by
precipitation using 0.1 V of NaCl 3 M and 2 V of ethanol 100%
and diluted in 75 ml of nuclease-free water. A standard agarose gel
electrophoresis was run to check the integrity of DNA. The total
DNA obtained was quantified with Nanodrop-1000 Spectropho-
tometer (Thermo Scientific) and with the QuantiT PicoGreen
dsDNA Assay Kit (Invitrogen).
Amplification of the 16S rRNA gene
For each sample a region of the 16S rRNA gene was amplified
by polymerase chain reaction (PCR). The primers used were the
universal E8F (5’-AGAGTTTGATCMTGGCTCAG-3’) with
adaptor A and 530R (5’-CCGCGGCKGCTGGCAC-3’) with
adaptor B using the sample-specific Multiplex Identifier (MID) for
pyrosequencing. The amplified region comprises hyper-variable
regions V1, V2 and V3. For each sample a 50 ml PCR mix was
prepared containing 5 ml of Buffer Taq (10X) with 20 mM
MgCl2, 2 ml of dNTPs (10 mM), 1 ml of each primer (10 mM),
0.4 ml of Taq Fast start polymerase (5 u/ ml), 39.6 ml of nuclease-
free water and 1 ml of DNA template. PCR was run under the
following conditions: 95u for 2 min followed by 25 cycles of 95u for
30 s, 52u for 1 min and 72u for 1 min and a final extension step at
72u for 10 min. The amplification process was checked by
electrophoresis in agarose gel (1.4%). PCR products were purified
using NucleoFastH 96 PCR Clean-Up Kit (Macherey-Nagel) and
quantified with Nanodrop-1000 Spectrophotometer (Thermo
Scientific) and with the QuantiT PicoGreen dsDNA Assay Kit
(Invitrogen). The pooled PCR products were directly pyrose-
quenced.
Total RNA extraction and double-strand cDNA synthesis
Total RNA was extracted from fecal samples using RiboPur-
eTM-Bacteria Kit (Ambion). DNase treatment was applied to
remove traces of genomic DNA from the eluted RNA using the
same kit. The integrity of RNA was checked by electrophoresis
in agarose gel (0.8%). The efficiency of the DNase treatment
was checked by amplifying each RNA sample by PCR. To
retro-transcribe total RNA into single-stranded cDNA the High-
Capacity cDNA Reverse Transcription Kit (Ambion) was used.
To synthesize double-stranded cDNA, 7.5 ml of Escherichia coli
ligase buffer (10X), 2 ml of dNTPs (10 mM), 0.2 ml of E. coli
RNAse H (5 u/ml), 3 ml of E. coli DNA pol I (10 u/ml), 0.5 ml of
E. coli ligase (10 u/ml) and 41.8 ml of nuclease-free water were
added to each single-stranded cDNA sample. The mixture was
placed in a Thermocycler at 15uC for 2 hours. Then, 2.5 ml of
T4 DNA polymerase (3 u/ml) were added and kept at 15uC for
30 min. The metatranscriptome obtained thus was purified by
precipitation and quantified using Nanodrop-1000 Spectropho-
tometer (Thermo Scientific) and the QuantiT PicoGreen
dsDNA Assay Kit (Invitrogen). A standard agarose gel electro-
phoresis was run to check the integrity of double-stranded
cDNA.
Pyrosequencing
For each sample, the total DNA (metagenome), double-stranded
cDNA and amplicons of the 16S rRNA gene were sequenced with
a Roche GS FLX sequencer and Titanium chemistry in the
company Life Sequencing (Valencia, Spain) and in the Center for
Public Health Research (CSISP-FISABIO) (Valencia, Spain). We
obtained an average of 58,928, 41,838 and 4,872 reads per
sample, respectively.
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Taxonomic assignment of 16S rRNA amplicons
We have used the Ribosomal Database Project (RDP)
pyrosequencing pipeline [24] to trim off the MID and primers
and to obtain the taxonomic classification. Sequences with a phred
quality score less than 20 (Q20) and short length (,250pb) were
discarded. We considered only annotations that were obtained
with a bootstrap value greater than 0.8, leaving the assignation at
the last-well identified level and consecutive levels as unclassified
(uc).
Taxonomic assignment of 16S rRNA transcripts
Due to the procedure followed to obtain the metatranscriptome,
the vast majority of transcripts belonged to ribosomal genes (16S
and 23S). The 16S rRNA reads were obtained from the total
cDNA by comparing the total reads against the Small Subunit
rRNA Reference Database (SSUrdb) [25] with BLASTN [26] and
an e-value of 10-16. All sequences with detected homology were
considered as 16S rRNAs and used to evaluate the phylogenetic
diversity of the active bacteria. The taxonomic classification was
performed in the same way as the amplicons.
Analysis of total and active microbiota
To study the phylogenetic structure of the bacterial community
we applied two approaches that involved the 16S rRNA gene. The
widely used analysis of 16S rRNA gene amplicons shows the
composition of the total microbiota (16S rRNA gene). However,
since the growing (active) bacteria contain more ribosomal RNA
than latent or starved cells, studying the 16S ribosomal RNA
transcripts enabled the active members of the microbiota to be
identified (16S rRNA transcripts) [12,22]. We calculated sample
diversity of the throughout the treatment for total and active
bacteria by applying three parameters: two richness estimators,
Chao1 [27] and the abundance-based coverage (ACE) [28], and
the Shannon index [29]. These estimators are implemented in
package Vegan [30] under R software (http://cran.r-project.org)
[31]. The biodiversity index and richness estimators were
calculated after sub-sampling with the multiple_rarefactions.py
script of QIIME to avoid the bias of the sequencing effort [32]. We
used heat maps based on taxonomic composition to study the
similarity between samples due to the relative abundance of each
taxon using the Vegan library in the R software (http://cran.r-
project.org) [30,31]. Canonical correspondence analysis (CCA)
was performed to determine the relation between the sample
composition and the class and mode of AB-treatment. To
statistically assess the effect of such factors on the bacterial
composition a multivariate ANOVA based on dissimilarity tests
(Adonis) was applied, as implemented in the package Vegan, R
software (http://cran.r-project.org) [30,31].
Metagenomics: functional analysis
To eliminate reads that were artifact replicates of pyrosequenc-
ing, we used the 454 Replicate Filter Program [33] with the
following parameters: sequence identity cutoff = 1; length
difference requirement = 0; number of beginning base pairs to
check = 10. Unique reads were compared against the human
genome using BLASTN [26] with an e-value of 10210 in order to
remove human sequences. To identify the sequences encoding the
ribosomal gene 16S rRNA we compared the dataset against the
Small Subunit rRNA Reference Database (SSUrdb) described in
Urich et al. [25] using BLASTN [26] with an e-value of 10216.
Sequences that did not give homology were used to identify the
reads corresponding to the ribosomal gene 23S rRNA by
BLASTN [26] against the Large Subunit rRNA Reference
Database (LSUrdb) described in Urich et al. [25] with an e-value
of 1024. Reads that matched with the LSUrdb were discarded.
The remaining reads were compared to the NCBI-nr protein
Table 1. Main features of the follow-up study.
Patient Antibiotic Mode of action/ Antimicrobial effect Pathology Sampling date Samples
A Moxifloxacin Cell replication inhibitor/ Bactericidal Bronchitis, pneumonia day0-before AB A_before
day3-during AB A3_D
day6-during AB A6_D
day10-during AB A10_D
day13-during AB A13_D
3 days after AB A_after
B Clindamycin Protein synthesis inhibitor/ Bacteriostatic Erysipelas day0-before AB B_before
day2-during AB B2_D
day5-during AB B5_D
day6-during AB B6_D
28 days after AB B_after
C Cefazolin/ Ampicillin/ Sulbactam Cell envelop synthesis inhibitor/ Bactericidal Infection pacemaker day0-before AB C_before
day3-during AB C3_D
day6-during AB C6_D
day10-during AB C10_D
3 days after AB C_after
D Amoxicillin Cell envelop synthesis inhibitor/ Bactericidal Chronic sinusitis maxillans day0-before AB D_before
day3-during AB D3_D
7 days after AB D_after
AB, antibiotic; D, during the treatment.
doi:10.1371/journal.pone.0080201.t001
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database using BLASTX [26] to identify the protein-coding genes.
Taxonomic assignment was based on the output of BLASTX
applying the lowest common ancestor (LCA) algorithm. Fasta files
were used to identify the Open Reading Frames (ORFs) by
applying the facility of Fraggenscan from the web server of
metagenomic analysis (WebMGA) [34]. To annotate the functions
of the predicted ORFs, we applied HMMER 3.0 program [35]
against TIGRFAM database [36] using default parameters. To
identify the genes involved in resistance to antibiotics, we
compared the identified ORFs against the Antibiotic Resistance
Genes Database by BLASTp [37] with an e-value of 10210. We
used the ShotgunFunctionalizeR package [38] in the R software
http://www.R-project.org/ [31] for functional comparison of
metagenomes. Specifically, we applied the testGeneCategories.-
dircomp function to compare the distribution of functional
categories between groups of samples. The test is based on a
Poisson model and compares each gene family of a higher
functional category to decide if the category is statistically
significant among two groups of samples [38].
Data accession number
All sequences have been entered in the European Bioinfor-
matics Institute database, under accession number ERP002192.
Results
Dynamics of total and active microbiota composition
throughout therapy
We analyzed total (16S rRNA gene) and active (16S rRNA
transcripts) microbiota from the four patients (A, B, C and D)
throughout AB treatment. The antibiotics administered to patients
A, C and D had a bactericidal antimicrobial effect, whereas in
patient B the effect was bacteriostatic. Regarding the mode of
action, the antibiotic used in patient A was a cell replication
inhibitor, in patient B it was an inhibitor of protein synthesis,
whereas patients C and D were treated with a cell envelop
synthesis inhibitor (Table 1). Each patient not only presented their
own microbiota profile for both total (Figure 1A) and active
(Figure 1B) microbiota before treatment, but also there was
apparently a rather large variation in bacterial taxa abundance
during and after treatment, which we describe succinctly. In
patient A, both total and active microbiota showed a high presence
of the families Lachnospiraceae (Coprococcus and Roseburia genera)
and Ruminococcaceae (Faecalibacterium, Blautia and Subdoligranulum
genera) during AB treatment with fluoroquinolone (Figure 1).
However, some genera such as Faecalibacterium and Subdoligranulum
were negatively affected by the AB, while others such as Blautia,
Coprococcus, Coprobacillus and Collinsella appeared to be resistant in
the first stage of treatment. We also found that the bactericidal
effect of AB had a negative impact on Bacteroides genus
(Bacteroidetes phylum) in the first days of treatment, but the
trend changed on day 13 with a great increase in its abundance.
Treatment with clindamycin of patient B resulted in a high
presence of Enterobacteriaceae (Escherichia, Salmonella genera), as
shown in Figure 1B. We also observed an increase in the Bacteroides
genus after the 5th day of treatment in active microbiota. For
patient C, Oscillibacteriaceae and Ruminococcaceae families
(Firmicutes phylum) as well as Rikenellaceae and Bacteroidaceae
(Bacteroidetes phylum) constituted the most abundant taxa in the
total microbiota (Figure 1A). The first important change occurred
on day 6 with an increase in Parabacteroides (Bacteroidetes phylum),
which remained abundant after treatment. However, in the active
microbiota we observed a shift towards the Bacteroidetes phylum
(Alistipes and Bacteroides genera) at the two last time points. On the
10th day of treatment, an increase in facultative anaerobic
families, Enterobacteriaceae (Proteobacteria) and Enterococcaceae
(Firmicutes) was found. Finally, in patient D, the initial microbiota
composition consisted mainly of Enteriobacteriaceae (Escherichia
genus) and Ruminococcaceae (Faecalibacterium genus). However,
both genera were greatly affected by the antibiotic as there was an
increase in resistant bacterial taxa of the Bacteroides genus
(Bacteroidetes).
After the AB course, patients A, C and D who received a
bactericidal antimicrobial agent clustered together in both cases,
total (Figure 2A) and active (Figure 2B) microbiota, apart from the
patient treated with a bacteriostatic antibiotic (patient B) (Figure 1
and 2). Moreover, we observed that the two patients treated with
cell envelope synthesis inhibitors (C and D) grouped together in
the case of the active microbiota (Figure 2B).
For all patients, the diversity parameters (Shannon index,
Chao1 and ACE estimators) of both total and growing microbiota,
showed notable fluctuations with a decrease in the number of
bacterial taxa and evenness on the first days of treatment (Figure
S1). At the end of the AB course, these three biodiversity
parameters increased but they did not reach the initial values
observed before AB therapy (Figure S1).
Effect of the class of antibiotic
To evaluate the pattern of variation shown by bacterial taxa or
gene abundances and its relationship with two variables (the
antimicrobial effect -bactericidal and bacteriostatic- and the mode
of action of the antibiotic -protein synthesis inhibitor, cell
replication inhibitor and cell envelope synthesis inhibitor-) we
applied a CCA at the different levels: 16S rRNA gene, 16S rRNA
transcripts, genes and the taxonomy of the identified coding
regions (gene taxonomy). The results showed that these two factors
(antimicrobial effect and mode of action) accounted for variability
in a particular direction and with different strength (Figure 3).
Figure 3A shows that the first axis explained 19% of variability,
splitting the total microbiota (16S rRNA gene) of the patients that
were medicated with bactericidal AB (patients A, C and D) from
the one treated with a bacteriostatic AB (patient B). The second
axis explained 12% of variability, placing the two groups of
samples treated with cell replication inhibitor (patient A) and
protein synthesis inhibitor (patient B) antibiotics on one side of the
graph; these ABs inhibit both essential and related cellular
processes, such as DNA replication and protein synthesis. By
contrast, the samples from patient C, treated with a cell envelope
synthesis inhibitor AB affecting synthesis of the bacterial cell wall,
fell on the other side of the graph. Both variables (antimicrobial
effect and mode of action) introduced significant variance in the
microbiota composition (Adonis test: p = 0.02, p = 0.04,
respectively).
Regarding active microbiota (Figure 3B), the first and second
axes explained 12% and 6% of the total variability, respectively.
With respect to the first axis, the samples from patient B (protein
synthesis inhibitor antibiotic) situated on the right side of the
graph. The latter AB, as occurred for the total microbiota,
introduced higher variance. The second axis separated the samples
taken from patients C and D, treated with cell envelope synthesis
inhibitor AB from the rest. Despite both factors, the antimicrobial
effect and mode of action were not significant (Adonis test: p =
0.18, p = 0.069), the second explained more variability (Adonis
test, p = 0.069).
The CCA applied at gene level (Figure 3C) showed a
distribution similar to that found for the total microbiota (Figure
3A), with the first and the second axes explaining 25% and 6% of
the total variance, respectively. The samples are separated chiefly
Responses of Gut Microbiota to Antibiotic Stress
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by antimicrobial effect and then by mode of action. However, in
this case the strength of the different vectors is weaker, probably
due to the great functional homogeneity of the gut microbial
community (Adonis test: antimicrobial effect p = 0.27, mode of
action p = 0.41).
Finally, we performed a CCA using the taxonomy of the
identified coding regions (Figure 3D). The two axes explained 19%
and 7% of the total variation of the data. As can be seen, the
different classes of antibiotics affected the taxonomy of the
identified coding regions in a similar way to the results reported
for total microbiota (Figure 3A) and gene analysis (Figure 3C)
(Adonis test: antimicrobial effect p = 0.044, mode of action p =
0.049).
Functional analysis of the metagenomes
The functional annotation of the ORFs was derived using the
TIGRFAM database, providing a hierarchical order: main roles,
the highest functional level (described in Figure S2), sub-roles,
more specific metabolic functions for each one of the main roles
and genes [36]. Regarding the main roles, the profiles were fairly
homogeneous for all patients and time points. The most abundant
categories before, during and after treatment were ‘‘Protein
synthesis’’, ‘‘Energy metabolism’’, ‘‘Cellular processes’’ and
‘‘Transport and Binding Proteins’’ with average values of relative
abundance of 13.5%, 13.2%, 9.6% and 9.5%, respectively, which
highlights the importance of these functions performed by the gut
microbiota (Figure S2). However, when considering the sub-roles,
Figure 1. Microbiota composition of patients A, B, C, and D. (A) total microbiota (16S rRNA gene) (B) active microbiota (16S rRNA transcripts).
The mode of action for each AB used is indicated.
doi:10.1371/journal.pone.0080201.g001
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we detected significant changes in the corresponding profiles for
each patient before, during and after treatment. For all patients we
detected a total of 53 sub-roles that differed significantly in gene
content (Table 2). Only two sub-role functional categories changed
significantly in all patients: ‘‘Menaquinone and ubiquinone’’
(within the main function ‘‘Biosynthesis of cofactors, prosthetic
groups, and carriers’’) and ‘‘Carbohydrates, organic alcohols, and
acids’’ (within the main function of ‘‘Transport and binding
proteins’’). Genes participating in the biosynthesis of menaquinone
and ubiquinone were under-represented during the treatment for
all patients, except in the case of patient B. Regarding the sub-role
of ‘‘Carbohydrates, organic alcohols, and acids’’ the gene
functions were overrepresented during the treatment in patients
A, B and C and under-represented in patient D. Most of the genes
belonging to this functional group were related to the phospho-
transferase system (PTS), which is essential for translocating
carbohydrates in bacteria [39]. Within this family, we have found
genes involved in the transport of various sugars such as mannose,
fructose, sorbose, glucitol or glucose. It is noteworthy that the
related sub-role ‘‘PTS’’ (within the main role ‘‘Signal transduc-
tion’’), associated to genes participating in regulation, was also
over-represented during the treatment in patients A and C and
under-represented in patient D.
The changes in the sub-roles ‘‘Biosynthesis and degradation of
surface polysaccharides and lipopolysaccharides’’ and ‘‘Other’’
(from the ‘‘Cell envelope main role’’) were significant in patients A,
B and D. In general, we detected a lower presence during
treatment of genes involved in the synthesis of lipopolysaccharides
(LPS). The sub-role ‘‘Pathogenesis’’ (within the main category
‘‘Cellular processes’’) and ‘‘Degradation’’ (within the ‘‘Fatty acid
and phospholipid metabolism’’ main category) decreased signifi-
cantly during treatment for patients A and D and increased in
patient B. The fatty acid and phospholipid metabolism genes were
involved in fatty acid beta-oxidation. On the contrary, the sub-role
‘‘Sporulation and germination’’ (within ‘‘Cellular processes’’) was
more abundant during treatment in patients A and D, with most of
the genes being involved in different stages of endospore
formation. Finally, we found that the sub-role ‘‘TCA cycle’’
(within the main category ‘‘Energy metabolism’’) and ‘‘Amino
acids, peptides and amines’’ (within ‘‘Transport and binding
proteins) underwent an increase in the number of genes encoding
different enzymes of the citric acid cycle during antibiotic
treatment for patient A and B and a decrease for D. Regarding
the transport of amino acids, peptides and amines, we found the
presence of genes encoding ABC transporters for amino acids and
urea.
Analysis of the resistome
We performed a search of the resistome by identifying AB
resistance genes in the 19 metagenomes analyzed by comparing
the predicted ORFs against the Antibiotic Resistance Genes
Database [37]. We identified the resistance genes that represented
0.2%, 0.8%, 0.22%, and 0.5% of the total determinants found for
patients A, B, C and D respectively. We found that while patients
A, B, and C showed an increase in resistance genes after
treatment, patient D presented the lowest relative abundance of
these determinants, decreasing from 0.81% to 0.14% (Figure 4A).
Figure 4B shows the profiles of resistance genes that varied during
the treatment for patient A, B and C, administered with antibiotics
belonging to different classes: fluoroquinolone, lincosamide and
beta-lactams, respectively (Table 1). Overall, we observed that the
resistance induced by each antimicrobial was associated with other
resistance determinants. Also, we found that its profiles matched
fairly well with the oscillatory dynamics of the surviving bacterial
community. Patient A showed an increase in the relative
abundance of the total resistance genes at the end of the
treatment, raising values from 0.18% before treatment to 0.28%
after the AB course. Fluoroquinolone resistance, multidrug
Figure 2. Heat map and clustering based on taxon composition and abundance. (A) total microbiota, (B) active microbiota. Colors in the
figure depict the percentage range of sequences assigned to main taxa (abundance .1% in at least one sample).
doi:10.1371/journal.pone.0080201.g002
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resistance efflux pump, appeared on day 10, when the microbiota
composition was dominated by the Firmicutes phylum, with high
abundance of members of the genus Enterococcus, described as
resistant to this type of antimicrobial [40]. This patient presented
high relative abundance of tetq gene, which confers tetracycline
resistance before and after the treatment, being Bacteroides genus
one of the most abundant taxa. Bacitracin profile showed a
maximum on day 6, with baca gene being associated to Streptococcus
and Clostridiales taxa (Figure 1 and 2). Patient B showed a strong
increase in the relative abundance of resistance genes during
treatment, increasing from 0.29% up to 0.89%. In fact all the
genes increased in abundance after AB treatment except those
involved in bacitracin resistance. The most remarkable increase
was found in a group of genes coding for multidrug resistance
efflux pump, which confer resistance against clindamycin and
related antimicrobials (aminoglycoside, glycylcycline, beta-lactam,
macrolide, and acriflavine). Patient C also showed an increase in
the total relative abundance of resistance genes at the last time
point and after treatment, from 0.16% to 0.36%. The genes that
code for multidrug resistance efflux pumps are the most abundant
on the 10th day of treatment. However, beta-lactamase genes
increased throughout the AB course and reached the maximum at
Figure 3. Canonical Correspondence Analysis (CCA) of the patients A, B, C and D in the follow-up study. (A) total microbiota, (B) active
microbiota, (C) genes and (D) gene taxonomy. The antimicrobial effect is represented as a vector with two levels (bactericidal and bacteriostatic). The
mode of AB action is represented as a vector with three levels (cell envelop synthesis inhibitor, cell replication inhibitor and protein synthesis
inhibitor).
doi:10.1371/journal.pone.0080201.g003
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Table 2. Functional profiles.
Patient
Main Role Sub-Role A B C D
Amino acid biosynthesis Glutamate family q 2.06E-004 NS NS NS
Histidine family q 0.02 NS NS NS
Serine family q 4.36E-004 NS NS q 0.01
Biosynthesis of cofactors* Biotin NS q 0.02 NS Q 2.33E-004
Glutathione and analogs NS q 2.95E-003 NS Q 0.04
Menaquinone and ubiquinone Q 0.02 q 2.19E-005 Q 0.04 Q 4.68E-003
Molybdopterin NS NS NS Q 4.35E-003
Pantothenate and coenzyme A q 0.01 NS NS NS
Other q 1.33E-004 NS NS NS
Cell envelope Biosynthesis and degradation of surface** Q 0.05 q 3.01E-005 NS Q 0.02
Other q 0.01 Q 0.01 NS q 0.02
Surface structures NS NS NS q0.04
Cellular processes Biosynthesis of natural products NS NS NS Q0.05
Cell division NS Q 0.01 NS q 3.07E-004
Chemotaxis and motility NS NS NS q0.01
Detoxification NS NS NS Q 0.04
DNA transformation Q 2.32E-003 NS Q 0.01 NS
Pathogenesis Q 9.43E-004 q 1.47E-005 NS Q 2.22E-009
Sporulation and germination q 0.03 Q 7.07E-017 NS q 2.65E-017
Toxin production and resistance NS Q 2.85E-004 NS NS
Central intermediary metabolism Amino sugars NS NS NS q 0.03
Nitrogen metabolism NS q 0.02 NS NS
DNA metabolism Chromosome-associated proteins NS NS Q 0.01 NS
Restriction/modification q 0.02 NS NS NS
Energy metabolism Aerobic Q 0.01 NS NS Q 0.01
Amino acids and amines NS q 9.26E-007 NS Q 2.22E-009
Anaerobic NS NS NS Q 4.80E-005
Biosynthesis and degradation of polysaccharides Q1.58E-003 NS NS NS
Chemoautotrophy NS Q0.01 NS NS
Electron transport NS q 0.01 NS NS
Entner-Doudoroff NS q 2.85E-004 NS Q 0.01
Fermentation NS NS NS q0.01
Pentose phosphate pathway NS q 0.01 NS Q 0.03
Sugars NS q 2.47E-005 NS Q 0.04
TCA cycle q 0.05 q 0.02 NS Q 4.59E-003
Fatty acid and phospholipid metabolism Degradation Q 0.05 q 0.04 NS Q 0.03
Protein fate Protein and peptide secretion and trafficking NS NS NS Q 0.02
Protein folding and stabilization NS Q 0.01 NS NS
Protein synthesis Other Q 0.03 Q 4.57E-005 NS NS
Ribosomal proteins: synthesis and modification NS Q 2.85E-004 NS q 4.80E-005
tRNA and rRNA base modification NS NS q 2.04E-003 NS
Regulatory functions Other NS NS q 0.01 NS
Signal transduction PTS q 1.40E-005 NS q 3.59E-009 Q 7.09E-009
Two-component systems NS NS NS Q1.52E-003
Transcription DNA-dependent RNA polymerase NS Q 4.49E-003 NS q 0.03
Transport and binding proteins Amino acids, peptides and amines q 4.36E-004 q 2.85E-004 NS Q 4.32E-005
Anions Q 4.36E-004 NS NS NS
Carbohydrates, organic alcohols, and acids q 4.36E-004 q 3.62E-006 q 1.46E-004 Q 3.76E-033
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the end of treatment. Patient C also presented a high abundance of
tetracycline resistance genes before treatment (teto, tetq and tetw)
associated to different taxa (Blautia, Bacteroides, Clostridium, and
Ruminococcus), which have been described as resistant to this
antibiotic [41,42,43] but underwent a dramatic decrease on day
10 associated with a major presence of the Proteobacteria phylum.
Discussion
Dynamics of the gut microbiota structure over the AB
course
The human gut microbiota consists of a highly complex
community whose members establish close relationships with the
host. ABs have strong direct and indirect effects on the human gut
microbiota and consequently on the functions they perform,
affecting the ecosystem maintenance and therefore host physiology
[7,13]. The microorganisms that carry certain genetic determi-
nants have an advantage under AB pressure, allowing them to
survive and grow. It is well known that the human gut microbiota
presents a high inter-individual variability and that its composition
depends on factors such as genetics, age, diet, health status and
AB-therapy, among others.
In our study, each patient presented their own initial microbiota
and thus there was an individual response to AB treatment with
fluctuations in the bacterial diversity and composition for both
total and active gut microbiota. These results highlight the
importance of the initial microbial structure in shaping the
changes in microbiota during the AB course. The individual
character of the response and incomplete recovery of initial
microbiota after AB treatment has previously been described by
Dethlefsen and coworkers [18] in a follow-up study of three
patients that received two courses of ciprofloxacin. However, we
also observed that the selection of resistant microorganisms led to a
similar microbiota composition after analogous antibiotic treat-
ment. Thus, AB seems to have a major impact on the structure of
the final bacterial community.
The gut microbiota has been described as an ecosystem that is
relatively resistant to perturbations [16]. However we observed
that a particular assembly of microorganisms can confer greater
resistance to a disturbance than others in terms of presence and
abundance of taxa, which could be related with the specific effect
of the AB. In patient A, there was a decrease in Faecalibacterium and
Bacteroides genera during the AB course, with AB-resistant strains
appearing at the end of treatment. However, on the first days of
treatment, other butyrate-producing taxa (Roseburia and Lachnospir-
aceae incertae sedis) and H2-consuming bacteria (Blautia, Collinsella
and Bifidobacterium) were present as active microbiota, obtaining
energy sources for the colonocytes of the host. A similar behavioral
pattern of these members of the intestinal microbiota has also been
reported by the above mentioned group of Dethlefsen et al.
[15,18] when they used ciprofloxacin, as in our patient A, an AB
belonging to the cell replication inhibitor group. In the case of
patient B, since clindamycin affected anaerobic bacteria, there
were marked decreases in Bacteroides and Blautia genera in the
active microbiota just after AB administration (Figure 2B).
However, three days later, high abundances of Bacteroides were
detected in the active bacterial community, suggesting these
bacteria acquired resistance. The presence of clindamycin-
resistant Bacteroides in gut microbiota has also been described in
other studies [9,44]. Moreover, we observed that the decrease in
anaerobic bacteria is compensated for by an important increase in
members of the family Enterobacteriaceae. Patients C and D were
treated with ABs which have a similar mode of action as both are
of the b-lactam class. As stated, the initial microbiota composition
was very different between both subjects, showing a differential
response to ABs. However, the active microbiota changed
throughout AB treatment with both patients acquiring a similar
composition by the end of it (Figure 2B). Patient C received a
combination of two ABs, Cefazolin and Ampicillin/Sulbactam,
which cover a broad spectrum of microorganisms and showed a
significant increase in Parabacteroides and Bacteroides genera.
Interestingly, resistance genes against ampicillin and cephalosporin
in these two taxa have been described previously [43]. On day 10
of treatment, an increase in the Enterobacteriaceae family
occurred and some of its genera, such as Escherichia or Klebsiella
are considered as opportunistic pathogens [45], suggesting that AB
use creates opportunistic infections by these harmful microorgan-
isms. Patient D was treated with amoxicillin, described as active
against some Proteobacteria such as Escherichia or Klebsiella. During
treatment, these genera were almost eliminated, whereas Bacteroi-
des, Blautia and Faecalibaterium taxa proved less susceptible to
treatment, as occurred in patient C. It is worth pointing out that
this bacterial profile, with Bacteroides, Blautia and Faecalibaterium
after the AB stress, has been found in the case of bactericidal
agents but not when a bacteriostatic antimicrobial was used.
Furthermore, a previous study [12] found a similar pattern of
active bacteria after beta-lactam treatment.
Antimicrobial effect and mode of action of ABs on the
gut microbiota
It has been stated that external variables such as ABs shift the
microbial composition [46]. In our study, the class of AB
Table 2. Cont.
Patient
Main Role Sub-Role A B C D
Cations and iron carrying compounds q 3.03E-003 NS NS Q 0.04
Nucleosides, purines and pyrimidines NS q 2.61E-003 NS Q 1.52E-003
Other NS q 1.33E-003 NS Q 5.56E-004
Porins NS q 0.01 NS NS
Unknown function Enzymes of unknown specificity Q 0.04 NS NS Q4.97E-005
Main roles and sub-roles that change significantly during treatment and their associated p-values (p-value , 0.05). The upward arrow indicates those categories that
were more abundant during treatment and the downward arrow those that were less abundant. NS, not significant.
*Biosynthesis of cofactors, prosthetic groups, and carriers.
**Biosynthesis and degradation of surface polysaccharides and lipopolysaccharides.
doi:10.1371/journal.pone.0080201.t002
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significantly shaped the microbiota on the basis of the antimicro-
bial effect (bactericidal or bacteriostatic) and the mode of action.
In addition, we have found that specific mechanisms of action
affect some organisms more than others, leading the bacterial
community towards an alternative temporary equilibrium state.
Clindamycin (protein synthesis inhibitor) introduced higher
variance in microbiota composition than the other agents, giving
way to a different bacterial community structure. This was
probably due to the bacteriostatic nature of clindamycin when
compared to the bactericidal effect of the other AB treatments.
Interestingly, in the case of the active microbiota representing the
surviving community, the bacterial composition was affected by
the mode of action rather than the antimicrobial effect clearly
distinguishing the three modes of action (Figure 3B). At a
functional level, the microbial community profile was driven by
the antimicrobial effect rather than by the mode of action.
However, the strength of the AB class, considered as an external
factor exerted at gene level was less intense, resulting in major
uniformity.
AB impact on bacterial metabolic functions
High homogeneity was observed in the main roles for all the
patients. This uniformity at a functional level has been also shown
in both DNA and RNA-based surveys [22,47,48,49,50] since the
microbiota is characterized by high functional redundancy. When
we considered sub-roles, 51% with significant variation corre-
sponded to inter-individual variability, representing the specific-
subject response to AB course. The over-representation of genes
involved in sugar transport in most of the patients suggested that
this functional category could play an important role under stress
conditions, as is the case of AB treatment. The phosphotransferase
system (PTS), in addition to its main role in sugar transport, which
is an essential function in itself, is involved in different regulatory
processes such as stress response in bacteria and, hence, it could
confer some extra advantages in presence of ABs [51]. Then, an
efficient system of importing sugars could facilitate the energetic
metabolism and, therefore, it could counteract the negative effect
of ABs on the bacterial growth. Pe´rez-Cobas and coworkers [12]
showed an increase in proteins belonging to the glycolysis pathway
and pyruvate metabolism, as well as higher expression of genes
related to energy metabolism/sugars category during beta-lactam
treatment.
As we mentioned previously, the bacteriostatic effect drives
the bacterial community to a characteristic composition, which
is also reflected at a functional level. In patient B, most of the
functional categories over-represented during treatment could
be related with the increase in Enterobacteriaceae members. In
this regard, we found an increase in the number of genes
involved in lipopolysaccharide synthesis, which is the main
component of the outer membrane for most Gram-negative
bacteria. This barrier plays an important role in nutrient
uptake and also confers resistance against ABs [52]. Likewise,
the genes of secretion systems typical of Gram negative
bacteria pathogenesis showed an increase only in patient B.
However, patients A, C, and D, who received bactericidal
treatment, presented a high abundance of Gram positive
Ruminococcaceae and Lachnospiraceae families, and an over-
representation of genes involved in endospore formation, a
resistance mechanism typical of Gram positive bacteria.
Another category that presented differences between bacteri-
cidal and bacteriostatic ABs was catabolism of fatty acids and
phospholipids, to produce acetyl-CoA through the beta-
oxidation process. As clindamycin inhibits mainly the anaer-
obic bacteria, the genes belonging to this sub-role were more
abundant in patient B whose bacterial composition proved rich
in Enterobacteriaceae family members.
Changes in the resistome
It has previously been pointed out that the AB usage is the
most influential agent in the spread and stabilization of
resistance genes in the gut environment [13]. One of the
multidrug resistant genes that increased in patients A and B
was a multidrug resistance efflux pump, which confers
resistance against aminoglycoside, glycylcycline, beta-lactam,
macrolide and acriflavine antibiotics. Since these ABs have
different properties such as spectrum or mode of action, the
transmission of these genes to a pathogen could hinder clinical
treatment in the event of infection. These resistance genes have
been described in some Proteobacteria genera such as
Escherichia or Klebsiella, thereby supporting the increase in the
abundance of these genera during treatment, principally in
patient B. Patients A, B and C reached higher values of gene
resistance abundances after AB treatment, with patient B, who
was treated with clindamycin, attaining maximum values. It
has been reported that besides the strong effect on the
microbial composition, clindamycin also promotes increased
AB resistance, which can persist in the microbial population for
a long time [53]. In contrast, patient D showed a decrease in
the relative abundance of resistance genes in the bacterial
community. In fact, we found different dynamics in patient D
as compared to the other three patients. This sample presented
an initial composition with prevalence of the Enterobacteria-
ceae family, which has been described as a considerable source
of resistance genes [54] and hence, the data indicated that
these taxa were strongly affected by the ABs. Thus, the final
resistome in the human gut after AB therapy would be
determined by the resistance genes carried by the surviving
bacteria and by the class of AB administered.
Conclusions
In this study, using high-throughput methodology, we have
provided new insights into the complex antibiotic resistance
scenario, related to the different modes of action of antibiotics and
the consequences for the gut microbiota composition and function
during antibiotic therapy. We have shown that specific properties
of ABs such as antimicrobial effects or mode of action, are
powerful forces for the selection of intestinal microbiota, and are
partially responsible for the shifts in bacterial composition during
AB therapy. The resulting structure of the microbial community
showed its specific metabolic capabilities giving a different
functional profile. Additionally, we have shown that the AB also
modified the resistome composition, increasing the abundance of
resistance genes in the gut environment, which is also important in
shaping the post-treatment composition of the microbiota.
However, further research into a larger group of subjects would
be necessary to establish a quantitative evaluation of changes in
gut microbiota.
Figure 4. Resistance gene profiles. (A) The dashed lines represent the relative abundance of the total number of resistance genes for patients A,
B, C, and D. (B) Relative abundance of the resistance genes throughout AB treatment for patients A, B, and C. The symbol "*" highlights the resistance
gene profiles which coincide with the antibiotic administered to patients C, A and B, respectively.
doi:10.1371/journal.pone.0080201.g004
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